A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non Small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hunan Cancer Hospital, Changsha, Hunan, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1.Diagnosed as advanced non-small cell lung cancer
2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation

Exclusion criteria

The patient is diagnosed with small cell lung cancer

Treatment and study plan

immunity therapy

Drug

The patient receives immunotherapy

Primary outcomes

PFS

Time frame: January 2021- January 2021 (1 year)

Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Sponsors and collaborators

Lead sponsor

Yongchang Zhang

Other

Collaborators

Hunan Province Tumor Hospital

Registry information

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Mar 2, 2021
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting